

## Freedom of Information (Scotland) Act 2002

<b>Date received</b>	22/08/2022	<b>Subject</b>	Drug Treatment		
<b>Passed to</b>	Pharmacy	<b>Date passed</b>	23/08/2022	<b>Respond by</b>	12/09/2022
<b>Category</b>	Research	<b>FOI number</b>	2022-337		

### Question/s to be answered

I am requesting the following information on behalf of Novartis.

The purpose of these questions is to understand the variability of treatment within your trust and apply that to the context of the rest of the country.

1. How many patients has your trust treated (for any disease) in the last 6 months (or the latest 6 months data you have available) with the treatments listed below:

- Revolade (eltrombopag)                      **1 patient**
- Nplate (romiplostim)                        **0**
- Doptelet (avatrombopag)                    **0**
- Tavlesse (fostamatinib)                    **0**

2. In the last 6 months (or the latest 6 months data you have available), how many patients has your trust treated for immune thrombocytopenia (ITP)?

**NHS Shetland has treated 1 patient in the first 6 months of 2022. This was identified by using ICD-10 Code D69.3 Immune thrombocytopenic purpura and includes only admitted patients. We do not hold data on patients treated in other settings.**

3. Of the patients treated for immune thrombocytopenia (ITP) in the last 6 months (or the latest 6 months data you have available), how many were treated with:

Rituximab                      **0 patients**

Mycophenolate mofetil **-unknown as the diagnoses the drug has being used for isn't clear or linked**

Surgery (splenectomy) **-unknown as the diagnoses the drug has being used for isn't clear or linked**

4. Does your trust participate in any ongoing clinical trials for immune thrombocytopenia (ITP)? If so, can you please provide the name of each trial along with the number of patients taking part?

**Not aware of.**